Last reviewed · How we verify
NCT05108051
Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir
Phase 1 trial testing ZSP1273 in Drug-drug Interaction in 36 participants. Completed in 17 March 2021.
17 March 2021
Quick facts
| Lead sponsor | Guangdong Raynovent Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 36 |
| Start date | 19 November 2020 |
| Primary completion | 17 March 2021 |
| Estimated completion | 17 March 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- ZSP1273 — full drug profile →
- Oseltamivir — full drug profile →
Conditions studied
- Drug-drug Interaction — all drugs for Drug-drug Interaction →
Sponsor
Guangdong Raynovent Biotech Co., Ltd — full company profile →
Who can join
Adults 18 to 45, any sex, with Drug-drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects.
Pang Y, Li H, Chen X, Cao Y, et al · · 2025 · cited 4× · PMID 39992105 · DOI 10.1128/aac.01729-24
Verify or expand the search:
- PubMed search for NCT05108051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ZSP1273
Trials testing the same drug.
- NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT06248567 — Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease · Phase 1 · completed
- NCT06157450 — Pharmacokinetics of ZSP1273 in Elder Participants · Phase 1 · completed
- NCT05954624 — Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid · Phase 1 · completed
Other recruiting trials for Drug-drug Interaction
Currently open trials in the same condition.
- NCT06381375 — Drug-drug Interactions With Anti-tuberculous Drugs · recruiting
- NCT06682325 — Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients · recruiting
- NCT05044962 — Kuwa Free! - Live Free! · NA · recruiting
Other Guangdong Raynovent Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07460284 — A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07139535 — A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · not yet recruiting
- NCT07139548 — A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05108051 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Raynovent Biotech Co., Ltd
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05108051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing